Treatment of Tinea Skin Infections
For tinea corporis and tinea cruris, use topical antifungal therapy (terbinafine or butenafine cream) for 2 weeks as first-line treatment, reserving oral therapy for extensive disease, treatment failure, or immunocompromised patients. 1, 2
Diagnostic Confirmation Before Treatment
- Confirm diagnosis with potassium hydroxide (KOH) preparation or fungal culture before initiating therapy, particularly for onychomycosis and tinea capitis 3
- Collect specimens using scalpel scraping, hair pluck, brush, or swab depending on the lesion location 1
- In clinically obvious cases with scale, lymphadenopathy, alopecia, or kerion, start empiric treatment immediately while awaiting culture results 4
Treatment by Site and Severity
Tinea Corporis and Tinea Cruris (Body and Groin)
Topical Therapy (First-Line):
- Apply terbinafine 1% cream or butenafine cream once or twice daily for 2 weeks 2, 3
- Continue treatment for at least 1 week after clinical clearing 2
- Topical therapy alone is sufficient for limited disease 1, 2
Oral Therapy (When Topical Fails or Extensive Disease):
- Terbinafine 250 mg daily for 1-2 weeks is particularly effective against T. tonsurans 1, 5
- Itraconazole 100 mg daily for 15 days achieves 87% mycological cure rate (superior to griseofulvin's 57%) 1
- Fluconazole 50-100 mg daily or 150 mg once weekly for 2-3 weeks is a third-line option 1, 5
Tinea Capitis (Scalp)
Oral therapy is absolutely required; topical treatment alone is never effective 4
Treatment Selection Based on Organism:
For Trichophyton species: Terbinafine is superior and preferred 4
- <20 kg: 62.5 mg daily for 2-4 weeks
- 20-40 kg: 125 mg daily for 2-4 weeks
40 kg: 250 mg daily for 2-4 weeks 4
For Microsporum species: Griseofulvin is more effective and preferred 4
Itraconazole (second-line): Active against both organisms 4
- 50-100 mg daily for 4 weeks or 5 mg/kg/day for 2-4 weeks 4
Tinea Pedis (Feet)
Topical Therapy:
- Terbinafine 1% cream once or twice daily for 1-2 weeks achieves >80% cure rates 8
- Allylamine medications require only 1-2 weeks of treatment 2
- Traditional azole therapy requires 4 weeks 2
Oral Therapy (for extensive or moccasin-type):
- Terbinafine 250 mg daily for 2 weeks 5, 3
- Itraconazole 100 mg daily for 2 weeks or 400 mg daily for 1 week 5
- Fluconazole 150 mg once weekly (pulse dosing) 5
Tinea Unguium (Onychomycosis)
Oral terbinafine is first-line therapy due to high cure rate, tolerability, and low cost 3
Treatment Failure Management
If mycology remains positive but clinical improvement is seen:
- Continue current therapy for an additional 2-4 weeks 4
If no clinical improvement:
- Assess for non-compliance, suboptimal drug absorption, organism resistance, or reinfection 4
- Switch agents: from terbinafine to griseofulvin for Microsporum, or to itraconazole 4
Essential Adjunctive Measures
- Screen all family members and close contacts for T. tonsurans infections, as >50% may be affected 1, 4
- Treat asymptomatic carriers with high spore loads systemically 4
- Clean all fomites (hairbrushes, combs, towels) with disinfectant or 2% sodium hypochlorite solution 1, 4
- Use antifungal shampoos (ketoconazole 2%, selenium sulfide 1%, or povidone-iodine) to reduce spore transmission 7
- Avoid skin-to-skin contact with infected individuals and do not share personal items 1
Treatment Endpoint and Monitoring
The definitive endpoint is mycological cure, not clinical cure 1, 4
- Repeat mycology sampling until clearance is documented 1, 4
- Clinical improvement alone is insufficient to stop therapy 4
- Follow-up should include both clinical and mycological assessment 1
Critical Pitfalls to Avoid
- Never use topical antifungals alone for tinea capitis—they do not penetrate hair follicles 4
- Do not use terbinafine for Microsporum infections—griseofulvin is superior 4
- Do not stop treatment based on clinical appearance alone—confirm mycological cure 1, 4
- Do not forget to screen household contacts, especially with T. tonsurans 1, 4
- Avoid using combination antifungal/steroid agents long-term due to risk of skin atrophy 2